Millions of people are affected by nonalcoholic steatohepatitis (NASH), which is a serious liver disease. A newly discovered amino acid compound has been found to successfully treat nonalcoholic fatty liver disease in non-human primates, representing a significant step towards the development of th
Nonalcoholic steatohepatitis is a serious liver disease that occurs when fat accumulates in the liver, leading to inflammation and scarring. It is a type of nonalcoholic fatty liver disease and is often associated with obesity, type 2 diabetes, and high cholesterol levels. Symptoms of NASH may not be present in the early stages, but as the disease progresses, it can lead to cirrhosis, liver failure, and even liver cancer.
NASH is the second stage of nonalcoholic fatty liver disease, which is estimated to affect 32% of people worldwide. While fatty liver disease can be treated with exercise and nutritional intervention, the liver damage from NASH is more permanent. It has become the primary cause of chronic liver disease, and NASH-related cirrhosis is now one of the most common reasons for liver transplantation.
While hundreds of compounds have successfully treated NASH in mice, including DT-109, Chen says mouse NASH models are limited because not all aspects of the human disease are accurately mimicked and, therefore, are not easily translatable to the clinic. The research team’s non-human primate model for NASH, confirmed using multi-omics profiling studies, is among the first to accomplish the feat.
“With this significant breakthrough in preclinical models, we can now consider evaluating DT-109 as a potential drug candidate for the treatment of NASH in future clinical trials,” said Jifeng Zhang, Ph.D., co-corresponding author and research associate professor of cardiovascular medicine at Michigan Medicine. “With millions of people suffering from NASH, the need for an effective treatment is more pressing than ever.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Powerful new obesity drug poised to upend weight loss careAs a growing number of overweight Americans clamor for Ozempic and Wegovy -- drugs touted by celebrities and on TikTok to pare pounds -- an even more powerful obesity medicine is poised to upend treatment.
Read more »
Powerful new obesity drug poised to upend weight loss careBased on the new results, company officials said they will finalize an application to the FDA for fast-track approval to sell it for chronic weight management.
Read more »
AstraZeneca says new COVID drug could guard against all variants of concern to dateThe drugmaker says the FDA could clear the new COVID drug for immunocompromised in months.
Read more »
New weight loss drug on fast-track to rival Ozempic, WegovyDrugmaker Eli Lilly said it's seeking FDA approval of its drug Mounjaro to treat weight loss after late-stage trials showed unprecedented results.
Read more »
New $50 billion weight loss drug could rival OzempicA study found that tirzepatide delivered weight loss results of up to 15.7 percent of a patient's body weight, an average of more than 34 pounds.
Read more »
Even Clouds Are Carrying Drug-Resistant Bacteria, New Study FindsFor a team of Canadian and French researchers, dark clouds on the horizon are potentially ominous not because they signal an approaching storm – but because they were found in a recent study to carry drug-resistant bacteria over long distances.
Read more »